Lead: A regulatory shift is reshaping preclinical MASH drug development: the FDA Modernization Act 2.0 (2022) removed the blanket animal-testing requirement from IND applications, and the FDA 2025 Roadmap to Reducing Animal Testing (April 2025) encourages validated NAMs such as organ-on-chip, organoids, and in silico models, starting from preclinical safety contexts (initially monoclonal antibodies). Against that backdrop, the strategic value of in vitro 3D human liver platforms for MASH has surged. This article compares two MASH-specific offerings (InSphero, CN Bio Innovations) plus one adjacent liver/intestine toxicology NAMs provider (VivoSim) — all with substantive public documentation — across platform architecture, cell composition, endpoints, throughput, and regulatory positioning. We do not list prices (direct quoting is always required).

Key Takeaways

NAMs regulatory context: FDA Modernization Act 2.0 and the 2025 Roadmap

Technical differences among InSphero, VivoSim, and CN Bio's 3D human liver platforms

Use-case-driven selection (compound triage, MoA validation, ADC hepatotoxicity, translational evidence)

How to integrate these platforms with in vivo CROs (Gubra / Physiogenex etc.)

📢 Editorial Disclosure This article is produced independently by our editorial team. We receive no monetary compensation, sponsored placement, or affiliate revenue from any of the three providers. See full disclosure at the end. For in-vivo-centric CROs, see Fibrosis CRO Landscape 2026.

This is not a market-share ranking, a recommended-vendor certification, or a price comparison. We cover platforms with publicly verifiable MASH or liver-NAMs data and organize their use-case fit; unpublished SOPs, pricing, regulatory acceptance, and capacity must be confirmed directly with each provider.

1. Why NAMs, Why Now — Regulatory Context

FDA Modernization Act 2.0 (2022)

Repealed the statutory requirement for animal testing in IND submissions. Sponsors may now submit organoid, organ-on-chip, 3D-constructed tissue, or in silico data when scientifically justified.

FDA 2025 Roadmap to Reducing Animal Testing

Published April 2025. Encourages organ-on-chip and in silico NAMs starting from preclinical safety — beginning with monoclonal antibodies before expanding to other biologics and new chemical entities — subject to validation and Context of Use.

Why MASH specifically

MASH has drawn regulatory-science attention — e.g., FDA qualified PathAI's AIM-NASH AI digital-pathology Drug Development Tool for MASH clinical trials in December 2025 — but that tool is for clinical-trial histology scoring, and in vitro MASH models as a class have not been designated an official NAMs priority indication. The interest in in vitro 3D models is driven by:

Long (>20-week) in vivo studies are expensive and show high site-to-site variability
Human-specific metabolic pathways (DNL, FFA handling) translate poorly from mouse/rat
Post-resmetirom (FDA approval, 2024), second-generation MASH programs need faster compound-triage cycles

The regulatory and technical environment increasingly supports adoption of in vitro 3D platforms. See Modernizing Preclinical Drug Development (ACS Pharmacol Transl Sci, 2025).

2. Platform Comparison

Attribute	InSphero 3D InSight™ Liver MASH	VivoSim NAMkind™ Liver	CN Bio Innovations PhysioMimix® MASH
HQ	Schlieren, Switzerland	San Diego, USA	Cambridge, UK
Technology	3D spheroid (static)	3D human liver spheroid (Organovo bioprinting lineage)	Liver-on-chip (MPS, perfusion)
Cell composition	4-cell co-culture: primary hepatocytes + Kupffer + endothelial + stellate	4-cell co-culture: primary hepatocytes + Kupffer + endothelial + stellate (NAMkind Liver)	3-cell tri-culture: primary hepatocytes + Kupffer + stellate (10:1:1)
MASH induction	FFA + LPS co-stimulus	MASH-specific induction not publicly documented (toxicology-led)	Proprietary HEP-Fat media
Culture duration	Up to 5 weeks	Extended culture	14 days – 1 month
Throughput	Akura™ 96 / 384 plates; 50 compounds per 5-week program	Mid throughput (print basis)	Mid throughput (plate basis)
Fibrosis endpoints	Pro-Collagen I, PIIINP, TIMP1, HA, Sirius Red, AI image analysis	NAMkind™ toxicology panel (detail on request)	Steatosis / inflammation / fibrosis markers (IL-6, IL-8, TNF-α, TIMP-1, Pro-collagen, Fibronectin, αSMA, etc.)
Metabolic / liver function	Triglycerides, LDH, single-spheroid transcriptomics	Hepatotoxicity markers incl. ADC validation data	ALT / AST, LDH, Albumin, Urea
MASH-specific public documentation depth	High (dedicated MASH page)	Low / toxicology-led (limited public MASH detail)	High (dedicated MASH page)
Regulatory track record	PharmaNest partnership (2026/2) for FibroNest™ AI fibrosis quantification	Explicit positioning against FDA 2025 Roadmap; presented ADC toxicity data at SoT 2026 (Mar 24; company PR)	Publishes on FDA Modernization Act 2.0; supported Inipharm INI-822 Phase 1 (2023)

For researchers tracking fibrosis & inflammation R&D

FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.

3. Provider Profiles

3-1. InSphero (Switzerland) — High-Throughput MASH Spheroid

Strengths

4-cell co-culture (hepatocytes + Kupffer + endothelial + stellate) covering the key non-parenchymal cells for MASH phenotypes
Akura™ 96 / 384 plates enable 50-compound / 5-week screening campaigns with 5-point dose-response in triplicate
Among the three selected here, the most extensively documented MASH-specific endpoint menu (per public information): Pro-Collagen I secretion, PIIINP, TIMP1, HA, TNF-α, MCP-1, MIP-1α, Sirius Red, single-spheroid transcriptomics, AI image analysis
February 2026 PharmaNest partnership integrates FibroNest™ AI fibrosis quantification
Steatotic donor and genetically diverse variants enable patient-heterogeneity assessment

Best for

Lead-optimization compound triage (many compounds in parallel)
MoA validation for first-in-class assets (transcriptomics-enabled)
Early assessment of patient heterogeneity (steatotic donor variants)

Caveats

Static spheroids do not reproduce flow-dependent pharmacology (e.g., sinusoidal shear-driven HSC activation)
Not optimized for very-long (>5 week) culture

📎 Reference: InSphero 3D InSight™ MASH

3-2. VivoSim (USA) — Liver/Novel-Modality Toxicology NAMs Riding the FDA Roadmap Wave

Strengths

Carries forward Organovo's bioprinting legacy (rebranded as VivoSim in April 2025); the current NAMkind™ Liver/Intestine is implemented as a 3D human liver spheroid model (reports 87.5% DILI sensitivity, 100% specificity)
Explicitly positioned against the FDA 2025 Roadmap to Reducing Animal Testing
Presented ADC (antibody-drug conjugate) hepatotoxicity and intestinal side-effect data at SoT San Diego on March 24, 2026 (company press release, not a peer-reviewed publication)
Commercial reach spans US, Europe, plus Korea and China via distributors

Best for

ADC and novel-modality hepatotoxicity NAMs assessment (only of the three to have presented ADC validation data, per company PR)
Programs intending to submit NAMs evidence directly to FDA
Asia-Pacific access (Korea, China)

Caveats

Current public information centers on liver/intestine toxicology, DILI, and ADC toxicity; MASH induction and MASH-specific endpoints (steatosis/inflammation/fibrosis) are not documented to the depth of the other two
Better characterized as a liver/novel-modality toxicology NAMs provider than as a MASH-specific platform

📎 Reference: VivoSim Press Release (Mar 2026 SOT, ADC data)

3-3. CN Bio Innovations (UK) — Liver-on-Chip with Perfusion and Long Culture

Strengths

PhysioMimix® Core MPS liver-on-chip (perfusion-based organ-on-chip)
3-cell tri-culture (hepatocytes + Kupffer + stellate) with proprietary HEP-Fat media MASH induction
14-day minimum, up to 1-month culture — accommodates fat-loading + compound dosing in a single experiment
PhysioMimix NASH-in-a-box reagent kit enables in-house adoption by sponsor labs
Per CN Bio's announcement, supported Inipharm INI-822 Phase 1 initiation (2023, NCT05945537) with in vitro data for regulatory submission
Transcriptomic profiling reportedly closer to human MASH patient profiles than mouse Western Diet models

Best for

Long exposure / flow-dependent efficacy and toxicity studies (>2 weeks)
Programs building translational evidence for regulatory submissions / pre-IND discussions
Sponsors wanting to adopt the assay in-house via the reagent kit

Caveats

MPS requires setup, SOPs, and operator training
Not designed for ultra-high-throughput screening (different design philosophy from 96/384 parallelization)

📎 References: CN Bio — PhysioMimix MASH / CN Bio — Modernization Act 2.0 Commentary

4. Selection Flowchart

Use-case shortlist

Use case	Primary	Secondary	Note
Compound triage (50+ compounds)	InSphero	CN Bio	InSphero offers 384-well; CN Bio plate parallel
MoA validation (transcriptomics)	InSphero	CN Bio	Both offer transcriptomics
Long exposure (>2 weeks)	CN Bio	InSphero	Perfusion-based stability
ADC / novel modality hepatotoxicity	VivoSim	InSphero	VivoSim publishes ADC validation data
Translational evidence	CN Bio	VivoSim	CN Bio Phase 1 support; VivoSim FDA Roadmap
In-house adoption (reagent kit)	CN Bio	—	NASH-in-a-box explicit offering
Patient heterogeneity	InSphero	—	Donor variants officially offered
Prioritization before in vivo	InSphero	CN Bio	Spheroid throughput wins

5. Integrating with In Vivo CROs

NAMs platforms do not replace in vivo work — they improve in vivo quality and cost efficiency when deployed as the upstream filter.

Typical MASH workflow:

[In-house library / synthesis] → [In vitro 3D (InSphero / CN Bio / VivoSim)]
                                  ↓ Top 5–10 compounds
                                  [In vivo MASH CRO (Gubra / Physiogenex)]
                                  ↓ Top 1–3 compounds
                                  [IND-enabling GLP tox (Charles River / Inotiv)]

Prioritizing 50 candidates in vitro to reduce the number advanced to in vivo lowers downstream in vivo cost
Species bridging (did-mouse-work-predict-human?) can be validated in vitro before paying for in vivo
When in vivo studies fail, in vitro MoA deep-dives can diagnose the failure mode

For in vivo options, see Fibrosis CRO Landscape 2026.

6. FAQ

Q1: Can in vitro 3D alone support an IND submission? A: Legally, non-animal nonclinical tests may be submitted under FDA Modernization Act 2.0, but whether they suffice stand-alone depends on Context of Use, the validation package, and prior discussion with FDA — examples of fully non-animal IND packages remain limited. Most sponsors currently run in vitro and in vivo in parallel or use in vitro as the primary evidence with in vivo as supportive. A pre-IND meeting to agree the validation package with FDA is the pragmatic path.

Q2: Other credible NAMs platforms? A: Emulate (Liver-Chip), Hesperos (multi-organ chip), TissUse (HUMIMIC), Mimetas (OrganoPlate) all publish MASH-adjacent work. We selected two with dedicated MASH pages (InSphero, CN Bio) plus VivoSim as an adjacent liver/novel-modality NAMs provider — all with verifiable public documentation. Future updates will expand the list.

Q3: Japan-based NAMs platforms? A: Several Japanese research institutes and university spin-outs are developing MPS / organoid platforms, though commercial MASH-specific services remain limited. Track the AMED MPS program and related initiatives for current state.

Q4: Rough price range? A: Prices are not public. These assays are often positioned as a lower-cost upstream screen versus a full 20-week GAN-diet in vivo study (N=10 × 6 groups), but actual pricing is quote-dependent and varies with compound count, endpoints, replicates, and analysis depth. Always obtain same-spec quotes for actual comparison.

Q5: Which provider leads on FDA-aligned regulatory positioning through 2026–2027? A: On the public record, CN Bio (explicit Modernization Act 2.0 messaging) and VivoSim (strong 2025 Roadmap positioning) lead on regulatory framing. InSphero differentiates via validation data accumulation through academic partnerships (PharmaNest, etc.). Note this reflects regulatory messaging / FDA-aligned positioning and should be distinguished from actual FDA submission acceptance or a qualified DDT. Leadership over the next 1–2 years will depend on actual FDA submission precedents.

CRO selection fundamentals
- CRO Selection Guide: Cost Drivers and 3-Point Quality Checklist
Comparison series
- Fibrosis CRO Landscape 2026
MASH models
- MASH Model Selection Guide: GAN / CDA / STAM
- AMLN vs GAN Diet: MASH Model Comparison
NAMs & methodology

Editorial Disclosure

This article is produced independently by our editorial team

We receive no monetary compensation, sponsored placement, or affiliate revenue from InSphero, VivoSim, or CN Bio Innovations

Ordering follows platform architecture grouping — not ranking

Sources: each provider's official website, public press releases, PubMed-indexed publications, and FDA public documents (as of May 2026)

Corrections or updates are welcome via our contact page

Reference sources:

Key Takeaways

NAMs regulatory context: FDA Modernization Act 2.0 and the 2025 Roadmap

Technical differences among InSphero, VivoSim, and CN Bio's 3D human liver platforms

Use-case-driven selection (compound triage, MoA validation, ADC hepatotoxicity, translational evidence)

How to integrate these platforms with in vivo CROs (Gubra / Physiogenex etc.)

📢 Editorial Disclosure This article is produced independently by our editorial team. We receive no monetary compensation, sponsored placement, or affiliate revenue from any of the three providers. See full disclosure at the end. For in-vivo-centric CROs, see Fibrosis CRO Landscape 2026.

This is not a market-share ranking, a recommended-vendor certification, or a price comparison. We cover platforms with publicly verifiable MASH or liver-NAMs data and organize their use-case fit; unpublished SOPs, pricing, regulatory acceptance, and capacity must be confirmed directly with each provider.

1. Why NAMs, Why Now — Regulatory Context

FDA Modernization Act 2.0 (2022)

Repealed the statutory requirement for animal testing in IND submissions. Sponsors may now submit organoid, organ-on-chip, 3D-constructed tissue, or in silico data when scientifically justified.

FDA 2025 Roadmap to Reducing Animal Testing

Why MASH specifically

Long (>20-week) in vivo studies are expensive and show high site-to-site variability
Human-specific metabolic pathways (DNL, FFA handling) translate poorly from mouse/rat
Post-resmetirom (FDA approval, 2024), second-generation MASH programs need faster compound-triage cycles

The regulatory and technical environment increasingly supports adoption of in vitro 3D platforms. See Modernizing Preclinical Drug Development (ACS Pharmacol Transl Sci, 2025).

2. Platform Comparison

Attribute	InSphero 3D InSight™ Liver MASH	VivoSim NAMkind™ Liver	CN Bio Innovations PhysioMimix® MASH
HQ	Schlieren, Switzerland	San Diego, USA	Cambridge, UK
Technology	3D spheroid (static)	3D human liver spheroid (Organovo bioprinting lineage)	Liver-on-chip (MPS, perfusion)
Cell composition	4-cell co-culture: primary hepatocytes + Kupffer + endothelial + stellate	4-cell co-culture: primary hepatocytes + Kupffer + endothelial + stellate (NAMkind Liver)	3-cell tri-culture: primary hepatocytes + Kupffer + stellate (10:1:1)
MASH induction	FFA + LPS co-stimulus	MASH-specific induction not publicly documented (toxicology-led)	Proprietary HEP-Fat media
Culture duration	Up to 5 weeks	Extended culture	14 days – 1 month
Throughput	Akura™ 96 / 384 plates; 50 compounds per 5-week program	Mid throughput (print basis)	Mid throughput (plate basis)
Fibrosis endpoints	Pro-Collagen I, PIIINP, TIMP1, HA, Sirius Red, AI image analysis	NAMkind™ toxicology panel (detail on request)	Steatosis / inflammation / fibrosis markers (IL-6, IL-8, TNF-α, TIMP-1, Pro-collagen, Fibronectin, αSMA, etc.)
Metabolic / liver function	Triglycerides, LDH, single-spheroid transcriptomics	Hepatotoxicity markers incl. ADC validation data	ALT / AST, LDH, Albumin, Urea
MASH-specific public documentation depth	High (dedicated MASH page)	Low / toxicology-led (limited public MASH detail)	High (dedicated MASH page)
Regulatory track record	PharmaNest partnership (2026/2) for FibroNest™ AI fibrosis quantification	Explicit positioning against FDA 2025 Roadmap; presented ADC toxicity data at SoT 2026 (Mar 24; company PR)	Publishes on FDA Modernization Act 2.0; supported Inipharm INI-822 Phase 1 (2023)

For researchers tracking fibrosis & inflammation R&D

FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.

3. Provider Profiles

3-1. InSphero (Switzerland) — High-Throughput MASH Spheroid

Strengths

4-cell co-culture (hepatocytes + Kupffer + endothelial + stellate) covering the key non-parenchymal cells for MASH phenotypes
Akura™ 96 / 384 plates enable 50-compound / 5-week screening campaigns with 5-point dose-response in triplicate
Among the three selected here, the most extensively documented MASH-specific endpoint menu (per public information): Pro-Collagen I secretion, PIIINP, TIMP1, HA, TNF-α, MCP-1, MIP-1α, Sirius Red, single-spheroid transcriptomics, AI image analysis
February 2026 PharmaNest partnership integrates FibroNest™ AI fibrosis quantification
Steatotic donor and genetically diverse variants enable patient-heterogeneity assessment

Best for

Lead-optimization compound triage (many compounds in parallel)
MoA validation for first-in-class assets (transcriptomics-enabled)
Early assessment of patient heterogeneity (steatotic donor variants)

Caveats

Static spheroids do not reproduce flow-dependent pharmacology (e.g., sinusoidal shear-driven HSC activation)
Not optimized for very-long (>5 week) culture

📎 Reference: InSphero 3D InSight™ MASH

3-2. VivoSim (USA) — Liver/Novel-Modality Toxicology NAMs Riding the FDA Roadmap Wave

Strengths

Carries forward Organovo's bioprinting legacy (rebranded as VivoSim in April 2025); the current NAMkind™ Liver/Intestine is implemented as a 3D human liver spheroid model (reports 87.5% DILI sensitivity, 100% specificity)
Explicitly positioned against the FDA 2025 Roadmap to Reducing Animal Testing
Presented ADC (antibody-drug conjugate) hepatotoxicity and intestinal side-effect data at SoT San Diego on March 24, 2026 (company press release, not a peer-reviewed publication)
Commercial reach spans US, Europe, plus Korea and China via distributors

Best for

ADC and novel-modality hepatotoxicity NAMs assessment (only of the three to have presented ADC validation data, per company PR)
Programs intending to submit NAMs evidence directly to FDA
Asia-Pacific access (Korea, China)

Caveats

Current public information centers on liver/intestine toxicology, DILI, and ADC toxicity; MASH induction and MASH-specific endpoints (steatosis/inflammation/fibrosis) are not documented to the depth of the other two
Better characterized as a liver/novel-modality toxicology NAMs provider than as a MASH-specific platform

📎 Reference: VivoSim Press Release (Mar 2026 SOT, ADC data)

3-3. CN Bio Innovations (UK) — Liver-on-Chip with Perfusion and Long Culture

Strengths

PhysioMimix® Core MPS liver-on-chip (perfusion-based organ-on-chip)
3-cell tri-culture (hepatocytes + Kupffer + stellate) with proprietary HEP-Fat media MASH induction
14-day minimum, up to 1-month culture — accommodates fat-loading + compound dosing in a single experiment
PhysioMimix NASH-in-a-box reagent kit enables in-house adoption by sponsor labs
Per CN Bio's announcement, supported Inipharm INI-822 Phase 1 initiation (2023, NCT05945537) with in vitro data for regulatory submission
Transcriptomic profiling reportedly closer to human MASH patient profiles than mouse Western Diet models

Best for

Long exposure / flow-dependent efficacy and toxicity studies (>2 weeks)
Programs building translational evidence for regulatory submissions / pre-IND discussions
Sponsors wanting to adopt the assay in-house via the reagent kit

Caveats

MPS requires setup, SOPs, and operator training
Not designed for ultra-high-throughput screening (different design philosophy from 96/384 parallelization)

📎 References: CN Bio — PhysioMimix MASH / CN Bio — Modernization Act 2.0 Commentary

4. Selection Flowchart

Use-case shortlist

Use case	Primary	Secondary	Note
Compound triage (50+ compounds)	InSphero	CN Bio	InSphero offers 384-well; CN Bio plate parallel
MoA validation (transcriptomics)	InSphero	CN Bio	Both offer transcriptomics
Long exposure (>2 weeks)	CN Bio	InSphero	Perfusion-based stability
ADC / novel modality hepatotoxicity	VivoSim	InSphero	VivoSim publishes ADC validation data
Translational evidence	CN Bio	VivoSim	CN Bio Phase 1 support; VivoSim FDA Roadmap
In-house adoption (reagent kit)	CN Bio	—	NASH-in-a-box explicit offering
Patient heterogeneity	InSphero	—	Donor variants officially offered
Prioritization before in vivo	InSphero	CN Bio	Spheroid throughput wins

5. Integrating with In Vivo CROs

NAMs platforms do not replace in vivo work — they improve in vivo quality and cost efficiency when deployed as the upstream filter.

Typical MASH workflow:

[In-house library / synthesis] → [In vitro 3D (InSphero / CN Bio / VivoSim)]
                                  ↓ Top 5–10 compounds
                                  [In vivo MASH CRO (Gubra / Physiogenex)]
                                  ↓ Top 1–3 compounds
                                  [IND-enabling GLP tox (Charles River / Inotiv)]

Prioritizing 50 candidates in vitro to reduce the number advanced to in vivo lowers downstream in vivo cost
Species bridging (did-mouse-work-predict-human?) can be validated in vitro before paying for in vivo
When in vivo studies fail, in vitro MoA deep-dives can diagnose the failure mode

For in vivo options, see Fibrosis CRO Landscape 2026.

6. FAQ

CRO selection fundamentals
- CRO Selection Guide: Cost Drivers and 3-Point Quality Checklist
Comparison series
- Fibrosis CRO Landscape 2026
MASH models
- MASH Model Selection Guide: GAN / CDA / STAM
- AMLN vs GAN Diet: MASH Model Comparison
NAMs & methodology

Editorial Disclosure

This article is produced independently by our editorial team

We receive no monetary compensation, sponsored placement, or affiliate revenue from InSphero, VivoSim, or CN Bio Innovations

Ordering follows platform architecture grouping — not ranking

Sources: each provider's official website, public press releases, PubMed-indexed publications, and FDA public documents (as of May 2026)

Corrections or updates are welcome via our contact page

Reference sources:

MASH 3D Liver CRO Comparison 2026: NAMs Platform Guide

1. Why NAMs, Why Now — Regulatory Context

FDA Modernization Act 2.0 (2022)

FDA 2025 Roadmap to Reducing Animal Testing

Why MASH specifically

2. Platform Comparison

For researchers tracking fibrosis & inflammation R&D

3. Provider Profiles

3-1. InSphero (Switzerland) — High-Throughput MASH Spheroid

3-2. VivoSim (USA) — Liver/Novel-Modality Toxicology NAMs Riding the FDA Roadmap Wave

3-3. CN Bio Innovations (UK) — Liver-on-Chip with Perfusion and Long Culture

4. Selection Flowchart

Use-case shortlist

5. Integrating with In Vivo CROs

6. FAQ

7. Related Reading

For researchers tracking fibrosis & inflammation R&D

Stay connected with Fibrosis-Inflammation Lab

Related Articles

Fibrosis CRO Landscape 2026: 5 Preclinical Providers

Fibrosis CRO Selection Criteria 2026: 7 Evaluation Axes

IPF Preclinical CRO Guide: Bleomycin, PCLS & Ashcroft (2026)

MASH 3D Liver CRO Comparison 2026: NAMs Platform Guide

1. Why NAMs, Why Now — Regulatory Context

FDA Modernization Act 2.0 (2022)

FDA 2025 Roadmap to Reducing Animal Testing

Why MASH specifically

2. Platform Comparison

For researchers tracking fibrosis & inflammation R&D

3. Provider Profiles

3-1. InSphero (Switzerland) — High-Throughput MASH Spheroid

3-2. VivoSim (USA) — Liver/Novel-Modality Toxicology NAMs Riding the FDA Roadmap Wave

3-3. CN Bio Innovations (UK) — Liver-on-Chip with Perfusion and Long Culture

4. Selection Flowchart

Use-case shortlist

5. Integrating with In Vivo CROs

6. FAQ

7. Related Reading

For researchers tracking fibrosis & inflammation R&D

Stay connected with Fibrosis-Inflammation Lab

Related Articles

Fibrosis CRO Landscape 2026: 5 Preclinical Providers

Fibrosis CRO Selection Criteria 2026: 7 Evaluation Axes

IPF Preclinical CRO Guide: Bleomycin, PCLS & Ashcroft (2026)